Shopping Cart
- Remove All
- Your shopping cart is currently empty
BTT-3033 is an orally active and potent α2β1 (EC50: 130 nM) inhibitor with an affinity for the α2I domain, inhibiting platelet binding to collagen I and cell proliferation. BTT-3033 induces apoptosis and can be used to study prostate cancer, inflammation, and cardiovascular disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $108 | In Stock | |
10 mg | $158 | In Stock | |
25 mg | $266 | In Stock | |
50 mg | $395 | In Stock |
Description | BTT-3033 is an orally active and potent α2β1 (EC50: 130 nM) inhibitor with an affinity for the α2I domain, inhibiting platelet binding to collagen I and cell proliferation. BTT-3033 induces apoptosis and can be used to study prostate cancer, inflammation, and cardiovascular disease. |
Targets&IC50 | α2β1:130 nM (EC50) |
In vitro | BTT-3033 and BTT-3034 inhibited cell adhesion to rat tail collagen I with EC50 values of 130 and 160 nM, respectively, and corresponding Emax values of 97 and 86% .Neither BTT-3033 nor BTT-3034 (at EC50 concentrations) inhibited the adhesion of MG-63 cells to vitronectin, 120-kDa fibronectin or 40-kDa fibronectin, assays that measured αV, α5β1, and α4β1 integrin function, respectively [2]. |
In vivo | Integrin α2β1 function blocking sulfonamides BTT-3016, BTT-3033(oral administration, 10 mg/kg) and BTT-3034 have anti-inflammatory effects in PAF-stimulated air pouch model[1]. |
Alias | BTT3033, BTT 3033 |
Molecular Weight | 465.5 |
Formula | C23H20FN5O3S |
Cas No. | 1259028-99-3 |
Smiles | CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1 |
Relative Density. | 1.35 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (214.82 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.